Cardica, Inc (NASDAQ:CRDC)
During Tuesday’s Afternoon trade, Shares of Cardica, Inc (NASDAQ:CRDC), gained 38.61% to $0.170. On December 16, Cardica, Inc. (CRDC) declared that it presented its responses to the questions raised by the U.S. Food and Drug Administration (FDA) on Cardica’s 510(k) submission for an expanded Indication for Use for the MicroCutter XCHANGE® 30. The responses to the FDA comprised the results from Cardica’s new chronic animal study conducted specifically in response to one of the FDA’s questions.
Cardica designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Cardica’s technology portfolio is intended to reduce operating time and facilitate minimally-invasive and robot-assisted surgeries. Cardica’s MicroCutter XCHANGE® 30, comprises a cartridge-based articulating surgical stapling device with a five-millimeter shaft diameter and staples, is manufactured and cleared for use in the United States for multiple open or minimally invasive surgical procedures for the transection, resection, and/or creation of anastomoses in small and large intestine in addition to the transection of the appendix.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH), inclined 11.14% to $4.99, during its current trading session.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) increased 10.69% and is at $4.97. Its total traded volume during recent trading session is 455,700.00 shares. The overall market worth of this company is about $191.27 million. The 52 week range of the stock remained $1.50 – $11.65.
Historically, the volatility of this stock is about 3.85% a week and 6.26% a month. Its latest closing price has a distance of 2.58% from SMA20 and is -38.41% from SMA200.
Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases counting systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.
Valeant Pharmaceuticals Intl Inc(NYSE:VRX)
Finally, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), dwindled -0.68%, and is now trading at $101.54. The company declared that its chairman and chief executive officer (CEO) J. Michael Pearson has taken a medical leave of absence, effective /files/includes/todays-hot-stories-pfizer-nysepfe-emc-corporation-nyseemc-att-nyset-spirit-realty-capital-nysesrc-154687-right.js away as he is being treated for pneumonia, according to Zacks
Consequently, the company’s board of directors has created an Office of the CEO to serve on an interim basis. This office will comprise Robert Chai-Onn, Executive Vice President and General Counsel; Dr. Ari Kellen, Executive Vice President and Company Group Chairman; and Robert Rosiello, Executive Vice President and Chief Financial Officer (CFO).
Additionally, the board created a committee to oversee and support the Office of the CEO. This committee comprises Robert A. Ingram, Lead Independent Director; G. Mason Morfit, President, ValueAct Capital; and Howard B. Schiller, former CFO of Valeant.
Valeant’s relationship with Philidor Rx Services, a specialty pharmaceutical company providing back-end services came under the scanner in Oct 2015 after it was alleged that the latter was urging pharmacy benefit managers to opt for expensive drugs over their cheaper generics. Consequently, Valeant terminated its relationship with Philidor, whereby it lost 20% of prescriptions and $250 million in sales in the fourth quarter. Subsequently, Valeant lowered its guidance for the fourth quarter of 2015 and the full year. Zacks Report
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.